![]() |
|
|
Vol. 296, Issue 1, 207-215, January 2001
Clinical Biochemistry Department, Istituto Superiore di
Sanità, Roma, Italy (R.P., P.Z., S.P., S.D.C.); and Pharmacology
Unit, Institut Municipal d'Investigació Mèdica (IMIM)
(C.H.L., M.F., P.N.R., J.O., J.S., R.d.L.T.), Universitat
Autònoma de Barcelona (M.F., P.N.R., R.d.L.T.) and Universitat
Pompeu Fabra (J.S.), Barcelona, Spain
Cell-mediated immune response and release of cytokines after the
administration of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") alone and in combination with ethanol were assessed in a
double blind, randomized, crossover, controlled clinical trial. Six
healthy male recreational users of MDMA participated in four different
experimental sessions, with a washout interval between sessions of 1 week, in which single oral doses of MDMA (100 mg), ethanol (0.8 g/kg),
the combination of both drugs, and placebo were tested. Acute MDMA
administration produced a time-dependent immune dysfunction in
association with serum concentrations of the drug as well as cortisol
stimulation kinetics. Although total leukocyte count remained
unchanged, there was a decrease in the CD4 T/CD8 T-cell ratio due to a
decrease in both the percentage and absolute number of CD4 T-helper
cells and simultaneous increase in natural killer (NK) cells. Ethanol
consumption produced a decrease in T-helper cells and B lymphocytes.
The combination of MDMA and ethanol caused the highest suppressive
effect on CD4 T cells and increasing effect in NK cells. Drugs
treatment produced a high increase of immunosuppressive cytokines
(transforming growth factor-
and interleukin-10) and a switch from
Th1-type cytokines (interleukin-2 and interferon-
) to Th2-type
cytokines (interleukin-4 and interleukin-10). Disregulation in the
production of pro- and anti-inflammatory cytokines with an unbalance
toward anti-inflammatory response was also observed. The immune
function shows a trend toward baseline levels at 24 h after MDMA
kinetics. This transient defect in immunological homeostasis, if
temporarily repeated, might alter the immune response with a risk for
the general health status.
This article has been cited by other articles:
![]() |
M. Mueller, F. T. Peters, H. H. Maurer, U. D. McCann, and G. A. Ricaurte Nonlinear Pharmacokinetics of ({+/-})3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") and Its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA That Develop After Typical Psychoactive Doses J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 38 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. H. Dumont and R. J. Verkes A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers J Psychopharmacol, March 1, 2006; 20(2): 176 - 187. [Abstract] [PDF] |
||||
![]() |
O M Zwick, D H Fischer, and J C Flanagan "Ecstasy" induced immunosuppression and herpes zoster ophthalmicus Br. J. Ophthalmol., July 1, 2005; 89(7): 923 - 924. [Full Text] [PDF] |
||||
![]() |
T. J. Connor, A. Harkin, and J. P. Kelly Methylenedioxymethamphetamine Suppresses Production of the Proinflammatory Cytokine Tumor Necrosis Factor-{alpha} Independent of a {beta}-Adrenoceptor-Mediated Increase in Interleukin-10 J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 134 - 143. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pacifici, S. Pichini, P. Zuccaro, M. Farre, M. Segura, J. Ortuno, S. Di Carlo, A. Bacosi, P. N. Roset, J. Segura, et al. Paroxetine Inhibits Acute Effects of 3,4-Methylenedioxymethamphetamine on the Immune System in Humans J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 285 - 292. [Abstract] [Full Text] |
||||
![]() |
R. Pacifici, P. Zuccaro, S. Pichini, P. N. Roset, S. Poudevida, M. Farre, J. Segura, and R. de la Torre Modulation of the Immune System in Cannabis Users JAMA, April 16, 2003; 289(15): 1929 - 1931. [Full Text] [PDF] |
||||
![]() |
C. Hernandez-Lopez, M. Farre, P. N. Roset, E. Menoyo, N. Pizarro, J. Ortuno, M. Torrens, J. Cami, and R. de la Torre 3,4-Methylenedioxymethamphetamine (Ecstasy) and Alcohol Interactions in Humans: Psychomotor Performance, Subjective Effects, and Pharmacokinetics J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 236 - 244. [Abstract] [Full Text] [PDF] |
||||